Literature DB >> 17008102

Synthesis and evaluation of peptidic irreversible inhibitors of tissue transglutaminase.

Christophe Pardin1, Steve M F G Gillet, Jeffrey W Keillor.   

Abstract

Herein we report the synthesis and the evaluation of eight novel compounds as irreversible inhibitors of transglutaminase (TGase). These compounds are based on a minimal peptidic scaffold shown previously [Chem. Biol.2005, 12, 469-475] to confer affinity for the TGase active site and bear electrophilic groups such as alpha,beta-unsaturated amide, chloroacetamide or maleimide; their general structure being Cbz-Phe-spacer-electrophile. The affinity conferred by the Cbz-Phe scaffold was determined by comparison to N-propylacrylamide and the length of the spacer was also varied to evaluate its importance. The inhibitory efficiencies (k(inact)/K(I)) of these compounds vary up to 10(5)M(-1)min(-1), among the highest reported for derivatives based on this simple Cbz-Phe peptidic scaffold.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008102     DOI: 10.1016/j.bmc.2006.09.011

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.

Authors:  Laila Dafik; Chaitan Khosla
Journal:  Chem Biol       Date:  2011-01-28

2.  Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.

Authors:  Bo Mi Ku; Se-Jin Kim; Nayeon Kim; Dongwan Hong; Yong-Bock Choi; Seon-Hyeong Lee; Young-Dae Gong; Soo-Youl Kim
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-08       Impact factor: 4.553

3.  Structure-activity relationships of hydrophobic alkyl acrylamides as tissue transglutaminase inhibitors.

Authors:  Alana M M Rangaswamy; Pauline Navals; Eric W J Gates; Sammir Shad; Sarah K I Watt; Jeffrey W Keillor
Journal:  RSC Med Chem       Date:  2022-01-26

4.  Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors:  Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal:  J Med Chem       Date:  2017-09-14       Impact factor: 7.446

Review 5.  Transglutaminase 2 inhibitors and their therapeutic role in disease states.

Authors:  Matthew Siegel; Chaitan Khosla
Journal:  Pharmacol Ther       Date:  2007-05-13       Impact factor: 12.310

6.  Activation and inhibition of transglutaminase 2 in mice.

Authors:  Laila Dafik; Megan Albertelli; Jorunn Stamnaes; Ludvig M Sollid; Chaitan Khosla
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

7.  Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition.

Authors:  Kim Y P Apperley; Isabelle Roy; Vincent Saucier; Nicholas Brunet-Filion; Sara-Pier Piscopo; Christophe Pardin; Élise De Francesco; Catherine Hao; Jeffrey W Keillor
Journal:  Medchemcomm       Date:  2016-12-05       Impact factor: 3.597

8.  The complex role of transglutaminase 2 in glioblastoma proliferation.

Authors:  Soner Gundemir; Alina Monteagudo; Abdullah Akbar; Jeffrey W Keillor; Gail V W Johnson
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.